Comparative Pharmacology
Head-to-head clinical analysis: ARISTADA versus DAPIPRAZOLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTADA versus DAPIPRAZOLE HYDROCHLORIDE.
ARISTADA vs DAPIPRAZOLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.
5 mg orally once daily, titrated as needed up to 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life of aripiprazole lauroxil (the prodrug in ARISTADA) is approximately 54 days (range 29-74 days) after IM injection, allowing monthly dosing.
Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment
Primarily renally excreted (approximately 60% as metabolites, <1% unchanged). Fecal elimination accounts for about 20%.
Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%)
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic